Cargando…
Fucoxanthin Is a Potential Therapeutic Agent for the Treatment of Breast Cancer
Breast cancer (BC) is one of the most common cancers diagnosed and the leading cause of cancer-related death in women. Although there are first-line treatments for BC, drug resistances and adverse events have been reported. Given the incidence of BC keeps increasing, seeking novel therapeutics is ur...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9229252/ https://www.ncbi.nlm.nih.gov/pubmed/35736173 http://dx.doi.org/10.3390/md20060370 |
_version_ | 1784734696326823936 |
---|---|
author | Lau, Tsz-Ying Kwan, Hiu-Yee |
author_facet | Lau, Tsz-Ying Kwan, Hiu-Yee |
author_sort | Lau, Tsz-Ying |
collection | PubMed |
description | Breast cancer (BC) is one of the most common cancers diagnosed and the leading cause of cancer-related death in women. Although there are first-line treatments for BC, drug resistances and adverse events have been reported. Given the incidence of BC keeps increasing, seeking novel therapeutics is urgently needed. Fucoxanthin (Fx) is a dietary carotenoid commonly found in seaweeds and diatoms. Both in vitro and in vivo studies show that Fx and its deacetylated metabolite fucoxanthinol (Fxol) inhibit and prevent BC growth. The NF-κB signaling pathway is considered the major pathway contributing to the anti-proliferation, anti-angiogenesis and pro-apoptotic effects of Fx and Fxol. Other signaling molecules such as MAPK, MMP2/9, CYP and ROS are also involved in the anti-cancer effects by regulating the tumor microenvironment, cancer metastasis, carcinogen metabolism and oxidation. Besides, Fx also possesses anti-obesity effects by regulating UCP1 levels and lipid metabolism, which may help to reduce BC risk. More importantly, mounting evidence demonstrates that Fx overcomes drug resistance. This review aims to give an updated summary of the anti-cancer effects of Fx and summarize the underlying mechanisms of action, which will provide novel strategies for the development of Fx as an anti-cancer therapeutic agent. |
format | Online Article Text |
id | pubmed-9229252 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-92292522022-06-25 Fucoxanthin Is a Potential Therapeutic Agent for the Treatment of Breast Cancer Lau, Tsz-Ying Kwan, Hiu-Yee Mar Drugs Review Breast cancer (BC) is one of the most common cancers diagnosed and the leading cause of cancer-related death in women. Although there are first-line treatments for BC, drug resistances and adverse events have been reported. Given the incidence of BC keeps increasing, seeking novel therapeutics is urgently needed. Fucoxanthin (Fx) is a dietary carotenoid commonly found in seaweeds and diatoms. Both in vitro and in vivo studies show that Fx and its deacetylated metabolite fucoxanthinol (Fxol) inhibit and prevent BC growth. The NF-κB signaling pathway is considered the major pathway contributing to the anti-proliferation, anti-angiogenesis and pro-apoptotic effects of Fx and Fxol. Other signaling molecules such as MAPK, MMP2/9, CYP and ROS are also involved in the anti-cancer effects by regulating the tumor microenvironment, cancer metastasis, carcinogen metabolism and oxidation. Besides, Fx also possesses anti-obesity effects by regulating UCP1 levels and lipid metabolism, which may help to reduce BC risk. More importantly, mounting evidence demonstrates that Fx overcomes drug resistance. This review aims to give an updated summary of the anti-cancer effects of Fx and summarize the underlying mechanisms of action, which will provide novel strategies for the development of Fx as an anti-cancer therapeutic agent. MDPI 2022-05-30 /pmc/articles/PMC9229252/ /pubmed/35736173 http://dx.doi.org/10.3390/md20060370 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Lau, Tsz-Ying Kwan, Hiu-Yee Fucoxanthin Is a Potential Therapeutic Agent for the Treatment of Breast Cancer |
title | Fucoxanthin Is a Potential Therapeutic Agent for the Treatment of Breast Cancer |
title_full | Fucoxanthin Is a Potential Therapeutic Agent for the Treatment of Breast Cancer |
title_fullStr | Fucoxanthin Is a Potential Therapeutic Agent for the Treatment of Breast Cancer |
title_full_unstemmed | Fucoxanthin Is a Potential Therapeutic Agent for the Treatment of Breast Cancer |
title_short | Fucoxanthin Is a Potential Therapeutic Agent for the Treatment of Breast Cancer |
title_sort | fucoxanthin is a potential therapeutic agent for the treatment of breast cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9229252/ https://www.ncbi.nlm.nih.gov/pubmed/35736173 http://dx.doi.org/10.3390/md20060370 |
work_keys_str_mv | AT lautszying fucoxanthinisapotentialtherapeuticagentforthetreatmentofbreastcancer AT kwanhiuyee fucoxanthinisapotentialtherapeuticagentforthetreatmentofbreastcancer |